Literature DB >> 8188737

Limited-sampling models for anticancer agents.

L J van Warmerdam1, W W ten Bokkel Huinink, R A Maes, J H Beijnen.   

Abstract

Pharmacokinetic parameters of antineoplastic drugs are usually generated from concentration/time profiles obtained after multiple venipunctures. With limited-sampling models (LSM) this number can be reduced to between one and three timed plasma samples. LSMs may facilitate population pharmacokinetic/pharmacodynamic studies, which eventually may lead to a dosing strategy based on the characteristics of the individual patient. In this article, the development, validation and application of several LSMs reported in the literature are reviewed.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8188737     DOI： 10.1007/bf01240143

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


  52 in total

1.  Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity.

Authors:  M J Ratain; R Mick; R L Schilsky; N J Vogelzang; F Berezin
Journal:  J Clin Oncol       Date:  1991-08       Impact factor: 44.544

2.  Use of adaptive control with feedback to individualize suramin dosing.

Authors:  H I Scher; D I Jodrell; J M Iversen; T Curley; W Tong; M J Egorin; A Forrest
Journal:  Cancer Res       Date:  1992-01-01       Impact factor: 12.701

3.  Reappraisal of some dosage adjustment guidelines.

Authors:  A Sulkes; J M Collins
Journal:  Cancer Treat Rep       Date:  1987-03

Review 4.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  L B Grochow; M Colvin
Journal:  Clin Pharmacokinet       Date:  1979 Sep-Oct       Impact factor: 6.447

5.  Choosing optimal sampling times for therapeutic drug monitoring.

Authors:  G E Schumacher
Journal:  Clin Pharm       Date:  1985 Jan-Feb

6.  A limited sampling method for estimation of the carboplatin area under the curve.

Authors:  B T Sørensen; A Strömgren; P Jakobsen; A Jakobsen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 7.  Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy.

Authors:  M J Moore; C Erlichman
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

8.  Anthracycline pharmacokinetics. Limited sampling model for plasma level monitoring with special reference to epirubicin (Farmorubicin).

Authors:  S Eksborg
Journal:  Acta Oncol       Date:  1990       Impact factor: 4.089

9.  Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580).

Authors:  B A Conley; A Forrest; M J Egorin; E G Zuhowski; V Sinibaldi; D A Van Echo
Journal:  Cancer Res       Date:  1989-06-15       Impact factor: 12.701

10.  Limited sampling models for amonafide (NSC 308847) pharmacokinetics.

Authors:  M J Ratain; A E Staubus; R L Schilsky; L Malspeis
Journal:  Cancer Res       Date:  1988-07-15       Impact factor: 12.701
View more
  15 in total

Review 1.  Pharmacokinetically guided administration of chemotherapeutic agents.

Authors:  H J van den Bongard; R A Mathôt; J H Beijnen; J H Schellens
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

2.  Comparison of stepwise and simultaneous estimations of population pharmacokinetics and pharmacodynamics of TS-943.

Authors:  A Furuya; N Kato; S Jingu; M Akimoto; O Kasai; T Suwa; M Sato; H Ogata
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Jul-Sep       Impact factor: 2.441

3.  Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide).

Authors:  Charlotte van Kesteren; R A A Mathôt; E Raymond; J P Armand; P Fumoleau; C Punt; M Ravic; J Wanders; J H Beijnen; J H M Schellens
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

Review 4.  Pharmacokinetic-pharmacodynamic guided trial design in oncology.

Authors:  Ch van Kesteren; R A A Mathôt; J H Beijnen; J H M Schellens
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

Review 5.  Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review.

Authors:  Milly E de Jonge; Alwin D R Huitema; Jan H M Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics and dose optimisation of carboplatin.

Authors:  S B Duffull; B A Robinson
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

7.  Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination.

Authors:  L J van Warmerdam; S Rodenhuis; O van Tellingen; R A Maes; J H Beijnen
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  A limited sampling method for the estimation of AUC and Cmax of carbamazepine and carbamazepine epoxide following a single and multiple dose of a sustained-release product.

Authors:  I Mahmood; N Chamberlin
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

9.  Caffeine in apnoeic Asian neonates: a sparse data analysis.

Authors:  How Sung Lee; Yok Moi Khoo; Yazmin Chirino-Barcelo; Kim Leong Tan; Dorothy Ong
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

Review 10.  Pharmacokinetic optimisation of treatment with oral etoposide.

Authors:  Giuseppe Toffoli; Giuseppe Corona; Barbara Basso; Mauro Boiocchi
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.